The United States Food and Drug Administration has classified three recalls, all dated 19 August 2026 and all ongoing, covering bulk active pharmaceutical ingredient supplied for prescription compounding: sildenafil citrate USP in 1 kg bags, and tadalafil USP in 1 kg and 0.5 kg bags. The stated reason is good manufacturing practice deviations found during an FDA inspection of the manufacturer, Shoolin Pharma Chem LLP.

What this is, and is not, matters. Class II means exposure may cause temporary or medically reversible adverse consequences, with a remote probability of serious harm — it is not a Class I safety emergency. The recall is of bulk raw material destined for compounding pharmacies, not of any finished licensed sildenafil or tadalafil product, so a patient on a branded or generic licensed tablet is not affected. And the trigger is a manufacturing quality failure identified on inspection, not an adverse event signal from patients: nobody has reported harm from these batches.

The practical relevance for a urology clinic is narrow but real where compounded phosphodiesterase-5 inhibitor preparations are used — troches, dissolvable formulations, combination products from compounding pharmacies. Those are common in some private practice settings. If you have patients on a compounded preparation, the question to ask the pharmacy is where the active ingredient was sourced. The broader point is a standing one: a compounded product carries the quality assurance of its supply chain, and that chain is shorter and less visible than a licensed manufacturer's.

Licensed sildenafil and tadalafil tablets are not affected; do not tell patients their prescription is recalled.
Identify any patients on compounded phosphodiesterase-5 inhibitor preparations and ask the pharmacy about ingredient sourcing.
Record whether a product is compounded or licensed in the notes; the distinction matters when a recall appears.
Treat a good manufacturing practice recall as a quality-assurance issue, not as a safety signal about the drug itself.
The position of Indian regulators on this manufacturer is not stated in the recall notice and should not be assumed.

Why it matters

It distinguishes a supply-chain quality failure from a drug safety problem, and the two get conflated the moment a patient hears the word 'recall'.

Don't overread it

This is an administrative recall for manufacturing deviations found on inspection — it is not evidence that anyone has been harmed, and it says nothing about sildenafil or tadalafil as drugs.